Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$44.62 - $62.75 $687,148 - $966,350
-15,400 Reduced 2.17%
695,400 $32.7 Million
Q2 2024

Aug 14, 2024

SELL
$51.17 - $68.18 $6.36 Million - $8.47 Million
-124,300 Reduced 14.88%
710,800 $38.4 Million
Q1 2024

May 15, 2024

SELL
$60.67 - $89.12 $19.1 Million - $28.1 Million
-315,400 Reduced 27.41%
835,100 $56.9 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $29.3 Million - $54.8 Million
759,400 Added 194.17%
1,150,500 $72 Million
Q3 2023

Nov 14, 2023

SELL
$45.39 - $59.0 $753,474 - $979,400
-16,600 Reduced 4.07%
391,100 $17.8 Million
Q2 2023

Aug 14, 2023

BUY
$43.47 - $67.77 $9.65 Million - $15 Million
221,900 Added 119.43%
407,700 $22.9 Million
Q1 2023

May 15, 2023

SELL
$41.0 - $56.12 $11.5 Million - $15.8 Million
-281,100 Reduced 60.21%
185,800 $8.4 Million
Q4 2022

Feb 14, 2023

BUY
$39.19 - $65.67 $9.37 Million - $15.7 Million
239,100 Added 104.96%
466,900 $19 Million
Q3 2022

Nov 14, 2022

SELL
$61.1 - $83.78 $17.6 Million - $24.1 Million
-288,100 Reduced 55.84%
227,800 $14.9 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.16B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.